Clinical trial · Interventional
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer
NCT00428610CI-TRIAL-00032583completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective is to determine whether LY573636-sodium (hereafter referred to as LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and CA-125 tests will be done before the first dose and then after every other treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Primary Peritoneal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LY573636-sodium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- LY573636
- description
- LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
- interventionNames
- Drug: LY573636-sodium
Primary outcomes (1)
- measure
- Percentage of Participants With Complete Response and Partial Response (Objective Response Rate)
- timeFrame
- Baseline to measured progressive disease up to 12.68 months
- description
- Objective response is complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.
Secondary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer * At least 18 years old * Have received at least one but no more than 2 systemic treatment regimens containing platinum (does not include regimens received before surgery for this cancer) * Have platinum-resistant disease Exclusion Criteria: * Have received more than 2 systemic treatment regimens for platinum-resistant disease * Serious pre-existing medical conditions * Actively receiving warfarin (Coumadin) for treatment of venous thrombosis or other prothrombotic conditions
References
Publications (0)
Data not yet available
No reference posted for this study.